Education
About Us
Working with TipRanks
Follow Us
Opthea Limited Sponsored ADR (OPT)
NASDAQ:OPT
RESEARCH TOOLSreports
OPT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.79 - $6.30
Previous CloseN/A
Volume12.29K
Average Volume (3M)35.20K
Market Cap
$463.95M
Enterprise Value$191.88M
Total Cash (Recent Filing)$157.07M
Total Debt (Recent Filing)$129.84K
Price to Earnings (P/E)―
Beta1.61
Next Earnings
Aug 28, 2025EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.32
Shares Outstanding153,886,830
10 Day Avg. Volume21,110
30 Day Avg. Volume35,197
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4209.28
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap0.41
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.54K
Enterprise Value/Ebitda-0.38
Forecast
1Y Price Target
$12.50Price Target Upside290.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Bulls Say, Bears Say
Bulls Say
Financial HealthOpthea has US $131.9 million in cash and equivalents, with a financial runway extending into the third quarter of 2025.
Market OpportunityOpthea held an investor day highlighting the commercial opportunity for sozinibercept (OPT-302) in wet AMD.
Therapeutic PotentialSozinibercept has a solid chance of showing meaningful vision gain on top of aflibercept.
Bears Say
Clinical Trial RisksDelays or unfavorable outcomes from the ongoing clinical trials could affect the company’s valuation.
Profitability ConcernsOpthea is a clinical-stage biotech company, and we do not expect it to be profitable on a continuing basis in the near term.
---
Ownership Overview
―
Insiders
<0.01% Mutual Funds
3.33% Other Institutional Investors
96.67% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
OPT FAQ
What was Opthea Limited Sponsored ADR’s price range in the past 12 months?
Opthea Limited Sponsored ADR lowest stock price was $1.79 and its highest was $6.30 in the past 12 months.
What is Opthea Limited Sponsored ADR’s market cap?
Opthea Limited Sponsored ADR’s market cap is $463.95M.
When is Opthea Limited Sponsored ADR’s upcoming earnings report date?
Opthea Limited Sponsored ADR’s upcoming earnings report date is Aug 28, 2025 which is in 156 days.
How were Opthea Limited Sponsored ADR’s earnings last quarter?
Opthea Limited Sponsored ADR released its earnings results on Feb 27, 2025. The company reported -$0.866 earnings per share for the quarter, missing the consensus estimate of -$0.13 by -$0.736.
Is Opthea Limited Sponsored ADR overvalued?
According to Wall Street analysts Opthea Limited Sponsored ADR’s price is currently Undervalued.
Does Opthea Limited Sponsored ADR pay dividends?
Opthea Limited Sponsored ADR does not currently pay dividends.
What is Opthea Limited Sponsored ADR’s EPS estimate?
Opthea Limited Sponsored ADR’s EPS estimate is -0.29.
How many shares outstanding does Opthea Limited Sponsored ADR have?
Opthea Limited Sponsored ADR has 153,886,830 shares outstanding.
What happened to Opthea Limited Sponsored ADR’s price movement after its last earnings report?
Opthea Limited Sponsored ADR reported an EPS of -$0.866 in its last earnings report, missing expectations of -$0.13. Following the earnings report the stock price went down -2.609%.
Which hedge fund is a major shareholder of Opthea Limited Sponsored ADR?
Currently, no hedge funds are holding shares in OPT
---
Opthea Limited Sponsored ADR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.50 (290.63% Upside)
$12.50 (290.63% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
―
20 days / 200 days
Momentum
-1.15%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-12.45%
Trailing 12-Months
Company Description
Opthea Limited Sponsored ADR
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused primarily on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
---
OPT Stock 12 Month Forecast
Average Price Target
$12.50
▲(290.63% Upside)
Technical Analysis
Omeros
―
EyePoint Pharmaceuticals
―
Aldeyra Therapeutics
―
Ocular Therapeutix
―
Arvinas Holding Company
―
Best Analysts Covering OPT
1 Year
1 Year Success Rate
2/8 ratings generated profit
1 Year Average Return
-19.75%
reiterated a buy rating 26 days ago
Copying Matthew Caufield's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -19.75% per trade.
---